Does T86.818 require prior authorization?

No, T86.818 does not require prior authorization (high confidence). Covered without prior authorization.

`T86.818`, Other complications of lung transplant

ICD-10-CM

No Prior Auth Required

Covered without prior authorization (high confidence)

Claims must be supported by medical record documentation of the patient’s diagnosis/clinical condition and justification that the selected drug, dose, and route of administration are appropriate and medically necessary for the non-oncologic indication.
Billing must comply with Medicare rules and any applicable LCD prior authorization or documentation requirements; follow any specific forms or prior authorization processes required by the LCD or payer.
Claims must be submitted with an ICD-10-CM code that represents the reason the procedure was performed, billed to the highest level of specificity, and linked to the appropriate CPT/HCPCS procedure code.
All documentation must be maintained in the patient's medical record, with every page legible, including appropriate patient identification and dates of service, and must include the legible signature of the physician or responsible non-physician practitioner.

Anti-neoplastic (chemotherapy) agent CPT/HCPCS codes may be used to bill for administration of these drugs when given to treat non-oncologic (noncancer) diagnoses if the drug is medically necessary for the patient’s condition and consistent with the standard of medical practice.
Monoclonal antibody agents and other biologic response modifiers may be administered and billed using chemotherapy administration codes for noncancer indications when the dose, route, and clinical use are appropriate and medically necessary.
Endovenous stenting is covered when used to treat severely symptomatic venous obstructions in accordance with LCD L38231.
Off-label IVIG use may be billed when supported by the applicable Local Coverage Determination (LCD) and by documentation of medical necessity; off-label is defined as not in Medicare-approved compendia or the FDA label.
IVIG may be used in bone marrow/stem cell transplantation when the recipient was CMV seropositive before transplantation, or after allogeneic transplantation for hematologic neoplasm when both donor and recipient were CMV seronegative.
IVIG may be used in solid organ transplantation when the donor was CMV seropositive and the recipient was CMV seronegative prior to transplantation.

CGS-J15-L34037, Flow Cytometry

J15

CGS-J15-L40139, MolDX: Molecular Testing for Solid Organ Allograft Rejection

J15

CGS-J15-L40140, MolDX: Molecular Testing for Solid Organ Allograft Rejection

J15

CGS-J18-L34037, Flow Cytometry

J18

CGS-J18-L40139

Ask Backwork about documentation requirements, denial risks, or coverage in your state.